Download PDF
Z Gastroenterol 2006; 44(10): 1065-1072
DOI: 10.1055/s-2006-927142
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

ASCO-Update 2006 - Neuigkeiten vom 42. Meeting der American Society of Clinical Oncology/ASCO 2006

ASCO Update 2006 - Highlights of the 42. Meeting of the American Society of Clinical Oncology/ASCO 2006A. Reinacher-Schick1 , D. Arnold2 , F. Lordick3 , M. Möhler4 , M. P. Lutz5 , T. Seufferlein6 [*] 1
  • 1Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
  • 2Klinik für Innere Medizin IV, Universität Halle
  • 3III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München
  • 4I. Medizinische Klinik und Poliklinik, Universität Mainz
  • 5Medizinische Klinik, Caritasklinik St. Theresia, Saarbrücken
  • 6Klinik für Innere Medizin I, Universitätsklinikum Ulm
Further Information

Publication History

Publication Date:
25 October 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Kaum ein Gebiet der Gastroenterologie hat sich in den letzten Jahren so schnell entwickelt wie die Therapie gastrointestinaler Tumoren, nicht zuletzt durch den Einsatz von Targeted Therapies. Wir möchten Ihnen in der folgenden Übersicht wie bereits im vergangenen Jahr [22] die wichtigsten neuen klinischen Studien zu Ösophagus-, Magen-, kolorektalen, Pankreas-, Leber- und Gallenwegskarzinomen vorstellen und bewerten, die auf dem diesjährigen Meeting der American Society of Clinical Oncology präsentiert wurden.

Abstract

Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review will give an overview on the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.

Schlüsselwörter

Ösophaguskarzinom - Magenkarzinom - kolorektales Karzinom - Pankreaskarzinom - Leberzellkarzinom - Gallenwegskarzinom - Targeted Therapies - klinische Studien

Key words

esophageal cancer - gastric cancer - colorectal cancer - pancreatic cancer - hepatobiliary cancer - targeted therapies - clinical trials

Literatur
(Angegeben sind jeweils die Nummern der Abstracts, die unter www.asco.org eingesehen werden können)

  • 1 Al-Batran S. et al . A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP).  JCO. 2006;  24 (18S) LBA4016
    PubMedGoogle Scholar
  • 2 Arnold D. et al . , Phase I/II study of cetuximab, capecitabine and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC).  JCO. 2006;  24 (18S) A3574
    PubMedGoogle Scholar
  • 3 Bosset J F. et al . Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22 921 trial.  JCO. 2005;  23 A3505
    PubMedGoogle Scholar
  • 4 Carr B I. et al . Gemcitabine hepatic arterial chemoembolization (TACE) in the treatment of unresectable HCC.  JCO. 2006;  24 (18S) A4141
    PubMedGoogle Scholar
  • 5 Cassidy J. et al . Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC).  JCO. 2006;  24 (18S) A3507
    PubMedGoogle Scholar
  • 6 Chauffert C. et al . Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study.  JCO. 2006;  24 (18S) A4008
    PubMedGoogle Scholar
  • 7 Chung K Y. et al . Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer.  JCO. 2006;  24 (18S) A3560
    PubMedGoogle Scholar
  • 8 Cohn A. et al . Single-agent pemetrexed in patients with advanced and metastatic hepatoma.  JCO. 2006;  24 (18S) A14064
    PubMedGoogle Scholar
  • 9 Cunningham D. et al . Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer.  New England Journal of Medicine. 2006;  355 11-20
    CrossrefPubMedGoogle Scholar
  • 10 Cunningham D. et al . Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial.  JCO. 2006;  24 (18S) LBA4017
    PubMedGoogle Scholar
  • 11 Czito B G. et al . Preliminary results of a phase I study of external beam radiation therapy (EBRT), oxaliplatin (OX), bevacizumab (BV), and capecitabine (CAP) for locally advanced or metastatic adenocarcinoma of the rectum.  JCO. 2006;  24 (18S) A3543
    PubMedGoogle Scholar
  • 12 Di Fabio F. et al . 18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study.  JCO. 2006;  24 (18S) A4061
    PubMedGoogle Scholar
  • 13 Eckel F. et al . Chemotherapy in advanced biliary tract carcinoma (BTC): A comprehensive analysis.  JCO. 2006;  24 (18S) A14036
    PubMedGoogle Scholar
  • 14 Feisthammel J. et al . Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinoma - a two-center phase II trial (GBFiri).  JCO. 2006;  24 (18S) A14088
    PubMedGoogle Scholar
  • 15 Fiorica F. et al . Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.  Gut. 2004;  53 925-930
    CrossrefPubMedGoogle Scholar
  • 16 Fuchs C. et al . A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C).  JCO. 2006;  24 (18S) A 3506
    PubMedGoogle Scholar
  • 17 Gerard J, Bonnetain F, Conroy T. et al . Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3 - 4 rectal cancers: results of the FFCD 9203 randomized trial.  JCO. 2005;  23 A3504
    PubMedGoogle Scholar
  • 18 Greer S E. et al . Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis.  Surgery. 2005;  137 172-177
    CrossrefPubMedGoogle Scholar
  • 19 Harder J. et al . Outpatient chemotherapy with gemcitabine and oxaliplatin in advanced biliary tract cancer; a phase II study.  JCO. 2006;  24 (18S) A14006
    PubMedGoogle Scholar
  • 20 Heinemann V. et al . Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.  JCO. 2006;  24 3946-3952
    CrossrefPubMedGoogle Scholar
  • 21 Hochster H S. et al . Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.  JCO. 2006;  24 (18S) A3510
    PubMedGoogle Scholar
  • 22 Hohler T. et al . ASCO-Update 2005 - Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005.  Z Gastroenterol. 2005;  43 1253-1259
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Igbal S. et al . A phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma.  JCO. 2006;  24 (18S) A4134
    PubMedGoogle Scholar
  • 24 Kang Y. et al . Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results.  JCO. 2006;  24 (18S) LBA4018
    PubMedGoogle Scholar
  • 25 Kawamoto T. et al . Amplification of HER-2/neu (erb2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC).  JCO. 2006;  24 (18S) A4011
    PubMedGoogle Scholar
  • 26 Kindler H L. et al . A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis.  JCO. 2006;  24 (18S) A4040
    PubMedGoogle Scholar
  • 27 Knox J J. et al . A phase II trial of oblimersen sodium (G3139) in combination with docorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5789.  JCO. 2006;  24 (18S) A14072
    PubMedGoogle Scholar
  • 28 Ko A H. et al . A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab in metastatic pancreatic cancer (PanCa).  JCO. 2006;  24 (18S) A4041
    PubMedGoogle Scholar
  • 29 Labianca R. et al . Alternating versus continuous „FOLFIRI” in advanced colorectal cancer (ACC): A randomized „GISCAD” trial.  JCO. 2006;  24 (18S) A3505
    PubMedGoogle Scholar
  • 30 Lin C. et al . Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial.  JCO. 2006;  24 (18S) A14129
    PubMedGoogle Scholar
  • 31 Machiels J P. et al . Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.  JCO. 2006;  24 (18S) A3552
    PubMedGoogle Scholar
  • 32 Maindrault-Goebel F. et al . OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study.  JCO. 2006;  24 (18S) A3504
    PubMedGoogle Scholar
  • 33 Marijnen C. et al . Long term results, toxicity and quality of life in the TME trial.  ASCO Gastrointestinal Cancers Symposium. 2006;  A166
    PubMedGoogle Scholar
  • 34 Moehler M. et al . Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interim analysis of a randomized German AIO phase II study.  JCO. 2006;  24 (18S) A4032
    PubMedGoogle Scholar
  • 35 Moore M J. et al . Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).  JCO. 2005;  23 A1
    PubMedGoogle Scholar
  • 36 Morinaga S. et al . Expression of Epidermal growth factor receptor (EGFR) associates with proliferation, apoptosis, and histologically aggressive features in hepatocellular carcinoma.  JCO. 2006;  24 (18S) A14039
    PubMedGoogle Scholar
  • 37 Nehls O. et al . A prospective multicenter phase II trial of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas: The final results.  JCO. 2006;  24 (18S) A4136
    PubMedGoogle Scholar
  • 38 Neuhaus P, Oettle H, Post S. et al . A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer.  JCO. 2005;  23 A4013
    PubMedGoogle Scholar
  • 39 Nordlinger P. et al . Complete radiological response of colorectal liver metastases (LM) chemotherapy: Does it mean cure?.  JCO. 2006;  24 (18S) A3501
    PubMedGoogle Scholar
  • 40 O’Dwyer P J. et al . Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203.  JCO. 2006;  24 (18S) A4143
    PubMedGoogle Scholar
  • 41 Poplin E. et al . Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201).  JCO. 2006;  24 (18S) LBA4004
    PubMedGoogle Scholar
  • 42 Qin SK. et al . Preliminary results of a phase II trial of FOLFOX4 regimen in Chinese patients with unresectable primary liver cancer.  JCO. 2006;  24 (18S) A14065
    PubMedGoogle Scholar
  • 43 Quirke P. et al . Local recurrence after rectal cancer resection is strongly related to the plane of surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial.  JCO. 2006;  24 (18S) A3512
    PubMedGoogle Scholar
  • 44 Ramanathan R K. et al . Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial.  JCO. 2006;  24 (18S) A4010
    PubMedGoogle Scholar
  • 45 Regine W F. et al . RTOG 9704a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma.  JCO. 2006;  24 (18S) A4007
    PubMedGoogle Scholar
  • 46 Richards D A. et al . Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer.  JCO. 2006;  24 (18S) A4071
    PubMedGoogle Scholar
  • 47 Rizk N P. et al . Impact of pre-operative chemoradiotherapy on post-esophagectomy morbidity and mortality.  JCO. 2006;  24 (18S) A4025
    PubMedGoogle Scholar
  • 48 Roedel K. et al . Multicenter phase II trial of preoperative radiotherapy with concurrent and adjuvant capecitabine and oxaliplatin in locally advanced rectal cancer.  ASCO Gastrointestinal Cancer Symposium. 2006;  A349
    PubMedGoogle Scholar
  • 49 Sauer R. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer.  N Engl J Med. 2004;  351 1731-1740
    CrossrefPubMedGoogle Scholar
  • 50 Schwartz J D. et al . Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein.  JCO. 2006;  24 (18S) A4144
    PubMedGoogle Scholar
  • 51 Sebag-Montefiore D. et al . Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial.  JCO. 2006;  24 (18S) A3511
    PubMedGoogle Scholar
  • 52 Shah M A. et al . Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447).  JCO. 2006;  24 (18S) A4020
    PubMedGoogle Scholar
  • 53 Sharma A. et al . Gemcitabine and oxaliplatin (Gemox) in advanced/unresectable gall bladder cancer: A phase II study.  JCO. 2006;  24 (18S) A14027
    PubMedGoogle Scholar
  • 54 Siegel A B. et al . Current treatments, determinants of use, and survival for patients with hepatoma in the United States from 1998 - 2002.  JCO. 2006;  24 (18S) A4138
    PubMedGoogle Scholar
  • 55 Stahl M, Stuschke M, Lehmann N. et al . Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.  JCO. 2005;  23 2310-2317
    CrossrefPubMedGoogle Scholar
  • 56 Tebbutt N. et al . Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer.  JCO. 2006;  24 (18S) A4067
    PubMedGoogle Scholar
  • 57 Tepper J E. et al . Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781.  JCO. 2006;  24 A 4012
    PubMedGoogle Scholar
  • 58 Urschel J D. et al . A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.  Am J Surg. 2003;  185 538-543
    CrossrefPubMedGoogle Scholar
  • 59 Venook A. et al . Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80 203 preliminary results.  JCO. 2006;  24 (18S) A3509
    PubMedGoogle Scholar
  • 60 Willett C G. et al . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.  Nat Med. 2004;  10 145-147
    CrossrefPubMedGoogle Scholar
  • 61 Yu S C. et al . Transarterial ethanol ablation of unresectable hepatocellular carcinoma with lipiodol-ethanol mixture (LEM): A phase II study.  JCO. 2006;  24 (18S) A14054
    PubMedGoogle Scholar
  • 62 Yu J. et al . A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer.  JCO. 2006;  24 (18S) A4013
    PubMedGoogle Scholar
  • 63 Zhu A X. et al . Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma.  JCO. 2006;  24 (18S) A14096
    PubMedGoogle Scholar

1 für die Arbeitsgemeinschaft Gastroenterologische Onkologie der DGVS.

Thomas Seufferlein

Klinik für Innere Medizin I, Universitätsklinikum Ulm

Robert-Koch-Str. 8

89081 Ulm

Email: thomas.seufferlein@uniklinik-ulm.de